chapter1.17
ALOES COMPOUND – Versatility in Gynaecological Practice
Introduction
Aloes Compound is an indigenous drug from ALARSIN Pharmaceuticals. The drug trial was conducted in Govt. Maternity Hospital, Tirupati. Seventy five patients were taken for study during the period of 1995-1997 for a period of 2 years. The drug was administered mainly as a drug for infertility. However, in some adolescent girls, in whom the hormone administration has limitations without full endocrine profile, the drug was administered to regularise the cycle. All the patients were studied after basic investigations. The results were encouraging both in fertility patients and adolescent girls.
Pharmacology
| Component | Quantity |
|---|---|
| Aloes Indica | 70 mg |
| Myrrh | 70 mg |
| Manjista | 35 mg |
| Karia (Iron) Bhasma | 30 mg |
| Hurmal | 35 mg |
| Kamboji | 30 mg |
| Jeevanti | 30 mg |
Each component of drug has its specific action like increasing the vascularity of the pelvic organs (Aloes indica) and stimulation of pelvic circulation. Hence useful in hypomenorrheic cycle.
Another component BALMYRRH which is haematinic, must have been working to improve the anaemic state of woman and thereby improving the general well-being and in particular intrauterine environment.
Selection of Patients
Seventy five patients were selected for our drug trial. Some of them were from Hospital practice and some from Consulting practice. All these patients underwent the basic investigations and hormonal estimations like TSH and prolactin estimation. In all the patient's tubal block was excluded.
Seventy five patients were divided into various groups as per age, marital status, as per the complaints, diagnosis and therapeutic evaluation and results (Tables 1, 2, 3 and 4).
Total No. of cases: 75
| Age | No. of Cases | Percent |
|---|---|---|
| 16-20 yrs | 15 | 20 |
| 21-25 yrs | 24 | 32 |
| 26-30 yrs | 30 | 40 |
| 31-35 yrs | 6 | 8 |
| Unmarried | Married | Total No. of Cases |
|---|---|---|
| 7 (10%) | 68 (90%) | 75 |
| Complaint-wise | No. of Cases | Percent |
|---|---|---|
| Irregular Periods | 20 | 31 |
| Andious to conceive | 52 | |
| Primary Sterility | 38 | 67 |
| Secondary Sterility | 14 | |
| Menorrhagia | 3 | 2 |
| Diagnosis | No. of Cases | Drug Administered | Duration of treatment | Results | Percent |
|---|---|---|---|---|---|
| Primary - Infertility | 38 | Aloes Compound | 3 months 1 tid |
||
| Secondary – Infertility | 14 | " | " | ||
| Infertility | 52 | " | " | 30 | 58 |
| Irregular cycles | 30 | " | " | 9 | 45 |
Results
After analysing the data, the response found:
- Infertility cases …. 50%
- Irregular cycles …..45 %
Discussion
The drug trial was conducted mainly in infertile group and concomitantly the drug was also tried in irregular cycles in adolescent group. The results were encouraging.
Two cases of Hyperprolactinemia were also tried, both of them conceived.
Conclusion
The drug Aloes Compound represents a broad spectrum of activity. In infertile woman, it is working like a fertility agent. In the adolescent girls, in whom hormonal preparations have limited role, Aloes Compound is working dramatically by regularising the cycle (working like a ovulation induction drug). It is presumed that each component of drug could be working in certain individuals in certain conditions. Mainly working as fertility agent in infertility, ovulation induction drug in irregular cycles, enhancing the glycogen content in hypoglycogen uterus and so on.
Aloes Compound is an indigenous drug, it may not withstand for challenges for its pharmacodynamics actions.
However, the drug is worth trying in:
- Adolescent girls.
- Obesity with Irregular Cycles.
- Infertile woman with low income group (who cannot afford sophisticated investigations and hormonal treatment).
The only side effect that is noticed is constipation (because of iron component). Hence, the drug can be taken for further research in the ground of good endocrinal laboratory.
Acknowledgement
My sincere thanks to ALARSIN Company who gave good encouragement by providing the drug and material and also my heartful thanks to Dr. P. Sarojini Devi, MD, DGO., Superintendent, Govt. Maternity Hospital, Tirupati, who has given permission to take up the patients for trial as well as my profound thanks to my all beloved Postgraduates who helped in this drug trial.
References
- Jagadeswari. S. - Indian J. of Clinical Practice. Vol. No. 6: PP. 47-48; Feb. 1996 (Clinical Trials of ALARSIN Products)
- Krishna Mukherjee. M.S. — Proceedings of 24th AICOG. New Delhi, 1972.
- Roshan R. Balsara – Indian Practitioner : 19 : 1. 123-125 : Jan. 1996.